Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 4.8%

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) were down 4.8% on Tuesday . The stock traded as low as $1.00 and last traded at $1.00. Approximately 507,917 shares were traded during trading, a decline of 72% from the average daily volume of 1,785,425 shares. The stock had previously closed at $1.05.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Adaptimmune Therapeutics in a report on Friday, December 29th. They set a “hold” rating for the company.

Adaptimmune Therapeutics Stock Performance

The stock has a market cap of $1.01 billion, a P/E ratio of -1.82 and a beta of 2.39. The firm has a 50-day moving average price of $1.42 and a 200-day moving average price of $0.91.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative return on equity of 155.39% and a negative net margin of 188.90%. The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $4.80 million. On average, research analysts predict that Adaptimmune Therapeutics plc will post -0.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC bought a new stake in shares of Adaptimmune Therapeutics in the 2nd quarter worth $46,000. Marquette Asset Management LLC purchased a new position in Adaptimmune Therapeutics during the third quarter valued at $77,000. Harbor Capital Advisors Inc. lifted its position in Adaptimmune Therapeutics by 9.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 13,317 shares in the last quarter. Key Client Fiduciary Advisors LLC lifted its position in Adaptimmune Therapeutics by 6.4% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 20,295 shares in the last quarter. Finally, Acuitas Investments LLC purchased a new position in Adaptimmune Therapeutics during the third quarter valued at $374,000. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.